CFMG & Wellpath in California — a documentary investigation · Article 027 of 100 · Series 3 — Physician executives, ownership and succession

Officer Is Not Owner: The Most Important Corporate-Governance Correction in the Record

Published

20 September 2026, 6:00 PM PT

Content last changed

20 September 2026, 6:00 PM PT

Public-evidence cutoff

20 September 2026, 6:00 PM PT

Sources checked

20 September 2026, 6:00 PM PT

Record through

20 September 2026, 6:00 PM PT

Editorial status

Public-source editorial review complete

Evidence note. This article relies on public records and distinguishes established fact, party position, allegation, judicial finding, inference and unresolved question. Nothing here is a finding that any identified corporation or individual violated California law unless a cited adjudicative source expressly says so.

Opening frame#

Officer Is Not Owner: The Most Important Corporate-Governance Correction in the Record is a governance inquiry, not a title-matching exercise. Corporate office, medical leadership, stock ownership, enterprise employment, and practical decision authority are treated as distinct evidentiary categories. The record is strongest where those categories converge in executed documents and weakest where succession or ownership instruments remain unavailable.

The governing question is narrow: Why do president, director, secretary, and medical-director titles fail to prove stock ownership? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.

I. The Question and the Public Record#

The relevant public record is best read cumulatively. No single branding statement, county agenda item, corporate filing, bankruptcy disclosure, or management agreement resolves the entire relationship. The evidentiary value comes from comparing documents created for different purposes and asking whether they converge on the same allocation of identity, authority, economics, and professional responsibility.

Why this is analytically important#

If the underlying filings truly say what the docket text says, the record raises an obvious question:

How could a California physician-owned professional corporation be identified in federal corporate-disclosure filings as the “corporate parent” of Wellpath LLC, a national management entity, while public corporate materials describe CFMG as a Wellpath affiliate?

There may be an innocent explanation: ECF relationship categories may have been selected imperfectly, the disclosure might have been drafted for conflicts purposes rather than corporate genealogy, or docket metadata may compress a more nuanced statement.

the record must not turn this into an accusation before reviewing the filings themselves.

But the repetition across more than one case means the issue is sufficiently concrete to justify a dedicated source-retrieval project.

open question: Very High.

Requested source set:

• exact PDF of interested-entity/corporate-disclosure filings in Beckner ;

• exact filings in Sand ;

• exact filings in Strieter ;

• exact filings in Avila ;

• equivalent filings in Venegas , Kukar-Tekano , Ayala , Pugh , and current CFMG cases.

The output should be a year-by-year table showing the relationship box or terminology actually used.

Raymond herr — the longest documented post-founder president#

The public record supports a strong chronology for Herr:

• April 2015 — identified in Shepherd evidence as CFMG Chief Medical Officer and President.

• March 2017 — signs CFMG collective-bargaining agreement as President.

• December 2017 — signs Stanislaus contract as President.

• 2018 — identified by Alameda County as CFMG Chief Medical Officer and President.

• September 2018 — CDPH lists him as President and Chief Medical Officer.

• 2018 — signs Fresno CFMG agreement as President.

• 2020 — appears on Placer agreement as CFMG President.

• September 8, 2021 — signs Monterey Amendment No. 2 as CFMG President.

This is a substantial run of formal corporate/contractual evidence.

It gives Herr an unusually important place in the governance history because his tenure spans:

• the mature H.I.G./CMGC period;

• the 2018 CCS–CMGC combination;

• the creation of the Wellpath brand;

• the 2019 MSA assignment to Wellpath LLC.

The key unanswered question is:

What happened to the CFMG shareholder, board, and Company Designee structure during the 2018–2019 Wellpath transition while Herr was president?

Richard medrano is a particularly important cross-role figure#

Richard Medrano, M.D., emerges as a CFMG corporate officer while simultaneously holding an operational role inside Wellpath.

Public Wellpath proposal materials identify Medrano as a Regional Medical Director and state that he joined Wellpath in 2017.

A 2024 county proposal says he oversees medical services in the West and Southwest region.

CFMG county contracts, meanwhile, identify him as:

• Vice President;

• Vice President & Secretary;

• Corporate Secretary;

• later Secretary.

Thus Medrano occupies both:

• a CFMG corporate-governance role;

• and a Wellpath regional clinical-management role.

This does not automatically undermine CFMG independence.

A physician can serve two affiliated entities.

But dual roles matter because the same physician may be expected to:

• act as a fiduciary/officer of CFMG;

• implement Wellpath regional clinical strategy;

• participate in decisions where the PC and MSO interests differ.

The high-value evidence is therefore conflict handling and actual decision records, not the mere fact of dual titles.

Scott kennedy enters the public CFMG corporate record#

Scott Herbert Kennedy, M.D., appears in the post-Herr CFMG structure.

An El Dorado County contract record from late 2022 identifies:

• Bazzel as President;

• Kennedy as Vice President/Treasurer.

By January 2025, the California Secretary of State identifies Kennedy as:

• Chief Financial Officer

• Director

He therefore clearly held formal CFMG corporate authority by 2025.

However, unlike Bazzel and Medrano, the present public source set does not yet permit the investigation to reconstruct Kennedy's pre-CFMG Wellpath/CCS role with equal confidence.

That gap should remain explicit.

the record should not infer a particular Wellpath executive history simply because Kennedy's CFMG address and email infrastructure are associated with the Wellpath enterprise.

The public governance record actually contains strong defense evidence#

An objective CPOM record must recognize that the governance history contains evidence supporting the legality of the structure.

• CFMG consistently existed as a separate California professional corporation.

• Physician presidents signed major county agreements.

• Current directors are physicians.

• CFMG remained a nondebtor PC during Wellpath bankruptcy.

• Post-bankruptcy contracts continue to be signed in CFMG's name.

• Wellpath publicly says CFMG is physician-owned.

• Hallman publicly said there was no ownership overlap.

• County contracts invoke ordinary corporate-signature formalities.

• The current Secretary of State filing names physician directors rather than Wellpath's nonphysician executive board.

These facts weigh against a simplistic "shell company" narrative.

The bankruptcy record also contains the strongest structural investigative evidence yet#

The same record identifies facts that require deeper review:

• Wellpath itself calls the model a friendly professional corporation structure.

• The PCs generated more than $674 million in annual revenue for the benefit of the Debtors .

• The Debtors remitted approximately $720 million in PC operating costs.

• The Debtors collected certain PC receivables.

• The Debtors handled payroll, benefits, taxes, and deductions for PC employees.

• The Debtors and certain physician owners were parties to Stock Transfer Agreements.

• Those agreements restricted transfer of physician shares.

• The stated purpose included continuation of the Debtors’ administrative services.

• The Debtors said they had authority under those agreements to ensure PCs remained licensed and qualified.

• The Debtors argued that Professional Corporation Contracts and organizational documents were executory contracts involving estate interests.

• The Debtors said they “maintain an interest” in the PCs.

• The motion uses the facially inconsistent phrase “ownership interests in the Professional Corporations.”

• The Debtors considered continued PC relationships essential to their own reorganization.

• New PC contracts during bankruptcy required five-business-day notice to DIP lenders and the Ad Hoc Group.

• CFMG litigation was sufficiently economically connected to Wellpath through insurance and indemnity that the Debtors repeatedly sought stay protection.

• No public CFMG-specific board record has yet been found showing an independent decision to continue with Wellpath during or after the restructuring.

None of these facts alone establishes unlawful control.

Together, they make the stock-transfer and board records indispensable.

II. Structural and Historical Context#

Records that would resolve the question#

• Actual Rule 7.1 / interested-entity PDFs from Beckner , Sand , Avila , Strieter , and post-bankruptcy CFMG cases.

• Every Overfield exhibit concerning Chapman termination.

• Chapman’s continued deposition once filed.

• Any renewed Hole deposition.

• Complete Smith same-entity stipulation and financial discovery record.

• Complete D.M. discovery correspondence supporting the same-functions representation.

• Complete Andrew Ho bankruptcy/arbitration references; public filings only.

• Napa Agreement 190201B and every amendment.

• County-by-county executed agreements and RFP proposals.

• CFMG/Wellpath quality-review policies implicated by Kartchner .

• Bankruptcy insurance/indemnity schedules naming CFMG.

• The 2012 MSA exhibits and every later amendment.

• All stock-transfer restriction / succession instruments referenced by the 2019 assignment.

• CFMG bylaws and shareholder/officer history.

• Physician employment templates pre-2018 vs post-2018.

• Wellpath enterprise clinical-policy approval matrices for California.

The correct treatment of the overlap#

the record should not invent a precise succession date from Fithian to Herr.

Possible explanations include:

• Fithian retained a founder/former-president title in pleadings describing earlier events;

• Herr assumed formal presidency during the middle of the decade;

• litigation allegations were historically dated rather than contemporaneous;

• different records used policy or medical titles imprecisely.

Until the corporate minutes and Secretary of State history are obtained, the transition should be described as:

By at least April 2015, Raymond Herr was being identified in contemporaneous operational records as CFMG President and Chief Medical Officer; litigation concerning earlier conduct continued to identify founder Taylor Fithian as President.

That formulation preserves the source conflict rather than silently resolving it.

Where the missing stock documents may exist#

Potential repositories include:

• CFMG corporate minute book;

• corporate counsel records;

• Wellpath legal department;

• management-company contract repository;

• bankruptcy diligence/data room;

• H.I.G. transaction files;

• lender diligence files;

• UCC/collateral documentation;

• former officer records;

• county due-diligence submissions if ownership certifications were required;

• malpractice/insurance underwriting files;

• California regulatory filings;

• tax records.

The 2019 assignment proves that at least some stock-transfer restriction instruments existed.

That makes their absence from the public record a retrieval problem, not a reason to assume their contents.

Shareholder-succession event table to build once the agreement is found#

For every historical owner transfer:

The likely historical periods needing reconstruction are:

• founder era;

• 2012–2013 H.I.G. transaction;

• Fithian/Herr transition;

• 2018 CCS–CMGC combination;

• Herr/Bazzel transition;

• 2024 bankruptcy;

• 2025 lender emergence;

• 2026 Local Government–California restructuring.

The chronology should remain blank where ownership is unproven rather than inferring ownership from officer titles.

III. The Control and Governance Analysis#

Subpages#

• Corporate timeline: 1983–2026

• The 2012 Management Services Agreement

• H.I.G. Capital and the 2013 investment

• The 2018 CCS–CMGC transaction and creation of Wellpath

• The 2019 management assignment

• CFMG physician ownership and governance

• California county contracts

• Physician employment and HR control

• Physician compensation and payroll

• Medical records and EHR control

• Clinical policy and operational control

• Litigation defense and claims administration

• Pre-bankruptcy litigation positions

• Bankruptcy and the rediscovery of CFMG

• Post-bankruptcy California litigation

• Smith v. Santa Cruz County

• D.M. v. County of Merced

• Hernandez v. County of Monterey

• Overfield v. Wellpath / CFMG

• Fresno case study: Miles, Henderson, and J.S.

• California CPOM law and 2026 enforcement

• Evidence matrix

• Case index

• Primary-document library

• Open questions / records not yet public

Every page should include a visible Evidence Level badge and a What this does not prove section.

The hallman "no ownership overlap" statement is important but not dispositive#

In November 2024, Wellpath board co-chair Kip Hallman told the Santa Barbara Independent that:

• CFMG was a wholly separate entity;

• it was owned primarily by group physicians;

• CFMG contracted with Wellpath for management services;

• the entities had no ownership overlap.

This is among the clearest contemporaneous public descriptions of formal ownership.

Santa Barbara County later described CFMG similarly as a separate physician-owned entity operating in California with a business relationship with Wellpath.

These statements materially undermine allegations that Wellpath or H.I.G. directly held CFMG physician stock.

But the statements do not answer:

• stock-transfer restrictions;

• succession control;

• veto rights;

• contractual replacement rights;

• collateral;

• management dependence;

• practical ability to replace the MSO.

"No ownership overlap" and "no control rights" are different propositions.

Reconstructing shareholder identity YEAR BY YEAR#

County contracts provide some direct corporate-signature evidence.

For example, a 2023 Placer County contract was executed for CFMG by:

• J. Bazzel as President;

• R. Medrano, M.D. as Secretary.

The document expressly invokes California Corporations Code section 313 execution formalities.

This supports the existence of functioning CFMG corporate officers.

The complete governance reconstruction should identify by year:

• shareholders;

• directors;

• president/CEO;

• secretary;

• CFO/treasurer;

• Company Designee;

• medical directors;

• any overlapping Wellpath positions.

The goal is not to imply wrongdoing from overlapping roles.

It is to identify which people actually carried the physician-corporation's legal authority.

Cfmg’s principal office moved into the post-bankruptcy Wellpath headquarters#

By November 2025, CFMG’s California Secretary of State filing listed its principal office as:

6550 Carothers Parkway, Suite 500, Franklin, Tennessee 37067

which is Wellpath’s post-bankruptcy corporate headquarters.

That is strong evidence of administrative integration after emergence.

It does not prove stock ownership, clinical control, or loss of physician governance.

But it demonstrates that after the bankruptcy, CFMG’s formal administrative locus became physically embedded at the reorganized Wellpath headquarters.

This should be compared with board/governance records to determine how physician corporate actions were actually processed.

The bankruptcy motion explains how Wellpath’s stock-transfer agreements generally functioned#

The November 12, 2024 Professional Corporation Motion supplies the enterprise-level explanation.

Wellpath described its PC model as a “friendly professional corporation” structure in which professional entities were owned by licensed physicians while Wellpath supplied management and administrative services.

The filing says the debtors and certain physician owners were parties to Stock Transfer Agreements that:

• restricted transfer of professional-corporation stock;

• facilitated orderly ownership transitions;

• supported compliance with professional-entity laws;

• addressed transfer events such as death and disability;

• promoted continuity of care;

• and promoted continued administrative services by the Wellpath debtors.

The filing further states that the debtors possessed authority under those agreements to help ensure that the PCs remained properly licensed and qualified.

Primary source:

In re Wellpath Holdings, Inc., No. 24-90533, Docket No. 15 (Bankr. S.D. Tex. Nov. 12, 2024).

https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1124325&docketNumber=15&projectCode=WPT&source=DM

These are major facts.

But the pleading refers generally to “certain PC Physicians.”

It does not say that every professional corporation had exactly the same transfer provisions.

Thus:

CFMG-specific assignment + enterprise-level description = strong reason to investigate, but not permission to invent the missing CFMG terms.

The “affiliated physician” language needs careful analysis#

Wellpath’s bankruptcy filings describe PC owners as licensed physicians “affiliated with” the Debtors.

That phrase is important but ambiguous.

“Affiliated” could describe:

• employment;

• consulting;

• board role;

• management role;

• shared business relationship;

• other contractual connection.

It does not necessarily mean:

• Wellpath shareholder;

• controlled person;

• employee.

For each CFMG shareholder, the record should identify the exact form of affiliation.

If the physician owner simultaneously depends on Wellpath for:

• employment;

• compensation;

• benefits;

• officer title;

• stock eligibility,

the combined leverage may be greater.

If the physician owner has independent professional/economic standing, the governance picture may differ.

H. What are the stock-transfer restrictions?#

The 2019 assignment references related stock-transfer restriction agreements.

The exact documents remain missing from the authenticated primary corpus.

That gap has become more important after the Attorney General's 2026 focus on physician-owner replacement and succession rights.

The defense must be able to show that Wellpath cannot:

• select the CFMG owner;

• compel transfer to its chosen successor;

• veto physician ownership;

• or effectively prevent CFMG from replacing the MSO.

If the restrictions are ordinary professional-corporation compliance devices, production should substantially strengthen the defense.

IV. Contrary Evidence, Limits, and Competing Explanations#

A disciplined analysis must begin its limiting case with the strongest contrary evidence: The central limitation is the missing shareholder/stock-transfer record. Physician corporate titles are genuine governance evidence but are not proof of ownership or independence under disagreement.

MADRID v. COUNTY OF TULARE — ENTITY CORRECTION WITH AN IMPORTANT CAUTION#

Case: Madrid et al. v. County of Tulare , E.D. Cal. No. 1:24-cv-00351.

In July 2025, the parties stipulated to replace Wellpath Management, Inc. with:

• California Forensic Medical Group, Inc.;

• Wellpath Liquidating Trust.

The stipulation recounts that outside bankruptcy counsel advised that CFMG was the proper medical entity.

Source:

https://docs.justia.com/cases/federal/district-courts/california/caedce/1%3A2024cv00351/443900/37

The stipulation also characterizes CFMG as a “subsidiary company of Wellpath Management Inc.”

That phrase should not be elevated to a judicial finding of ownership.

It appears in a party stipulation explaining a pleading correction and may reflect imprecise entity terminology.

It conflicts with stronger evidence indicating CFMG is physician-owned and legally separate.

The proper use of Madrid is therefore:

strong evidence that bankruptcy forced a defendant-identity correction; weak evidence of actual stock ownership.

By 2026, CFMG and the clinician defendant had separate identified counsel appearances as “Medical Defendants.”

V. Missing Documents and Falsification Tests#

The record remains incomplete in material respects. Key unresolved points include the actual shareholder ledger, stock-transfer agreement, succession minutes, and the explanation for contradictory parent/subsidiary/affiliate filings.

The central missing documents are now the stock-transfer restrictions#

The January 1, 2019 Assignment of Management Services Agreement is a critical instrument.

It identifies:

• CFMG as the "Company";

• Wellpath LLC as the new "Manager";

• Wellpath Management, Inc., formerly Correctional Medical Group Companies, Inc. and California Forensic Management Group, Inc., as the "Outgoing Manager."

The operative language does more than assign the MSA.

It states that the outgoing manager:

irrevocably assigns the Management Services Agreement to Wellpath LLC along with any related or incidental instruments including but not limited to relevant stock transfer restriction agreements .

That sentence is one of the most consequential facts uncovered in the entire project.

The stock-transfer restrictions were important enough to be expressly carried into the Wellpath structure along with the MSA.

Yet the actual agreements have not been located in the public corpus in the public record.

That creates a Tier One evidentiary gap.

The bankruptcy did not reorganize CFMG stock through the debtor plan#

Because CFMG was a nondebtor professional corporation, the Wellpath Chapter 11 did not simply convert CFMG stock into lender equity in the manner that debtor-company equity was restructured.

That distinction matters.

Wellpath itself announced in May 2025 that ownership of the reorganized Wellpath enterprise transitioned to a group of current and former lenders.

Public SEC filings by Prospect Capital show that its Wellpath debt was converted into debt and equity positions in New WPCC Parent, LLC . Prospect subsequently reported holdings including Series A Preferred Interests and Class A Common Interests in New WPCC Parent.

Those records illuminate the new ownership of the management enterprise.

They do not establish that New WPCC Parent owns CFMG's physician stock.

The more precise question is:

What happened to the MSA, stock-transfer restrictions, management rights, security interests, and succession mechanisms when the Wellpath management enterprise changed ownership?

That is the post-bankruptcy continuity issue.

Shareholder#

The shareholder owns the professional corporation's stock.

Because CFMG is a California professional medical corporation, stock ownership is subject to California professional-corporation restrictions.

A shareholder's identity must be established through:

• stock ledger;

• stock certificate;

• shareholder agreement;

• transfer record;

• corporate minutes;

• authenticated corporate filing or admission.

A title alone is insufficient.

November 21, 2025 — the officer/director roster remains the same, but the principal office moves#

A second California Secretary of State Statement of Information filed November 21, 2025 , File No. BA20252267299 , identifies the same officers:

• Grady Judson Bazzel — CEO

• Richard J. Medrano — Secretary

• Scott Kennedy — CFO

and the same three directors:

• Bazzel;

• Medrano;

• Kennedy.

But the corporate-address picture changes.

The principal office becomes:

6550 Carothers Parkway, Suite 500, Franklin, Tennessee 37067

while the mailing address and officer/director addresses remain:

3340 Perimeter Hill Drive, Nashville, Tennessee 37211

The filing lists no California office .

This is a meaningful administrative fact.

The Franklin address is publicly identified as Wellpath's current headquarters.

Thus by late 2025 CFMG's principal-office filing had moved from the prior Nashville Wellpath location to the reorganized Wellpath headquarters in Franklin.

That is strong evidence of corporate-administrative integration.

It is not evidence of stock ownership.

The current shareholder question remains unanswered#

This is perhaps the most important conclusion of the prior analysis.

The January and November 2025 California Statements of Information tell us:

• officers;

• directors;

• addresses.

They do not tell us:

• shareholders;

• share percentages;

• stock certificates;

• beneficial ownership;

• succession rights.

Wellpath has publicly described CFMG as physician-owned.

Kip Hallman publicly described it as owned primarily by a group of physicians and said there was no ownership overlap with Wellpath.

Those are meaningful corporate statements.

But the actual ownership schedule has not yet been obtained.

Accordingly, the record should not publish:

• "Bazzel owns CFMG";

• "Bazzel, Medrano and Kennedy are the shareholders";

• "Taranath is a CFMG shareholder";

• "Wellpath owns CFMG";

• "H.I.G. owns CFMG stock."

None of those propositions is currently established by sufficiently reliable primary evidence.

Section 313 signature records are strong officer evidence#

Several county agreements contain explicit California Corporations Code section 313 execution language.

For example, Placer's contract states that a corporation should be signed by officers from specified statutory categories unless a board resolution authorizes otherwise.

Those records are valuable because they provide stronger evidence of corporate office than casual website biographies.

Thus:

• Herr signing as President;

• Bazzel signing as President;

• Medrano signing as Vice President/Secretary;

• Kennedy signing as VP/Treasurer;

should be treated as significant corporate acts.

They still do not establish share ownership.

Primary documents now required to complete the ownership chain#

The next document-production/retrieval priority is:

• CFMG stock ledger from 2012 to present.

• Every issued/cancelled stock certificate.

• Shareholder roster by year.

• Share percentages.

• CFMG shareholder agreements.

• Stock-transfer restriction agreements referenced in 2019 assignment.

• Buy-sell agreements.

• succession agreements.

• options.

• proxies.

• nominee/custodial agreements.

• death/disability succession provisions.

• license-loss succession provisions.

• employment-linked stock provisions.

• retirement/resignation transfers.

• board approvals of every stock transfer.

• shareholder approvals.

• valuations/purchase-price records.

• source of funds for each transfer.

• any MSO consent/veto rights.

• any security interest involving shares.

• all Company Designee appointments.

• bylaws from 2012 to present.

• articles/amendments.

• Statements of Information for every year available.

• board/director minutes.

• shareholder meeting minutes.

• written consents.

• conflict-of-interest policies.

• 2012 MSA approval resolutions.

• 2019 assignment approval resolutions.

• post-bankruptcy MSA ratification/continuation resolutions.

• 2026 Local Government–California authorization records.

2025 SECRETARY OF STATE FILINGS SHOW A PHYSICIAN BOARD DURING THE BANKRUPTCY ERA#

Project records from the California Secretary of State identify, in January 2025:

• Grady Judson Bazzel — Chief Executive Officer / Director;

• Richard J. Medrano — Secretary / Director;

• Scott Kennedy — Chief Financial Officer / Director.

That means the formal CFMG board during the bankruptcy period was physician-composed.

This is meaningful evidence favoring the formal professional-corporation structure.

It also allows the governance question to be framed concretely:

What did Bazzel, Medrano, and Kennedy decide, in their CFMG capacities, about the Chapter 11 and continuation of the Wellpath MSA?

That is much more useful than asking abstractly whether “CFMG” approved the reorganization.

WHAT WOULD CONSTITUTE STRONG CONTRARY EVIDENCE?#

The following would be substantially more consequential:

• Wellpath or lender documents selecting CFMG’s shareholder successor without meaningful physician choice;

• stock-transfer instruments requiring continuation of Wellpath as manager;

• CFMG board action occurring only after Wellpath implementation;

• automatic continuation of the MSA despite a formal assignment/ownership change requiring consent;

• documents showing the Wellpath side could replace the CFMG owner/director;

• lender covenants directly controlling CFMG governance;

• CFMG unable to terminate the manager without losing its stock, contracts, accounts, records, or operating assets.

No such CFMG-specific document has yet been established publicly in this investigation.

That is precisely why the missing stock and governance instruments matter.

The bankruptcy record sharpens the central cpom question#

The bankruptcy evidence does not prove that Wellpath practiced medicine through CFMG.

It does something more useful.

It reveals the architecture of dependence .

The Debtors themselves described:

• a friendly-PC structure;

• physician ownership;

• deep administrative control;

• major economic reliance on PC revenues;

• stock-transfer restrictions tied to management continuity;

• authority relating to PC licensing/qualification;

• insurance;

• payroll;

• collections;

• taxes;

• legal support;

• indemnification;

• lender notice over new PC contracts.

California law then asks a separate question:

Did those structural rights and dependencies remain on the lawful administrative side of the line, or did they give the nonprofessional management enterprise practical or contractual authority over decisions reserved to physicians?

That question still requires the CFMG-specific stock, board, and authority records.

Article v.f makes the missing stock agreements more, not less, important#

One might initially assume that confirmation rendered the stock-transfer issue irrelevant. The opposite is true.

If the MSA was broadly assumed together with related agreements and interests, then determining the exact scope of the CFMG-related instruments becomes even more important.

The 2019 Assignment expressly links the MSA, related/incidental instruments, and stock-transfer restriction agreements. The bankruptcy PC Motion separately describes stock-transfer agreements as part of the friendly-PC system and says they support continuity of Debtor administrative services. Article V.F then uses broad language about modifications, amendments, supplements, restatements, related agreements, options, rights, and interests.

The convergence of those documents means the CFMG-specific stock instrument should now be treated as a Plan-continuity document , not merely a historical ownership document.

The exact instrument could reveal whether ownership-succession control also crossed the May 9, 2025 restructuring boundary.

CONTROL TEST FOUR — CAN THE PHYSICIAN OWNER REMOVE OR REPLACE WELLPATH?#

The Art Center framework makes reciprocity important.

The relevant comparison is:

Can Wellpath replace the physician owner?

versus:

Can the physician owner replace Wellpath?

The 2012 MSA gives CFMG termination rights for specified manager breaches and insolvency events.

But the public MSA does not show an unrestricted right for CFMG to terminate simply because its physician owners prefer another MSO.

The agreement was:

• exclusive;

• initially ten years;

• automatically renewable in five-year periods;

• economically integrated with management fees, funding, banking, and collateral.

That does not itself make CFMG captive.

But if the missing stock agreement also provides that the physician owner loses ownership when attempting to remove Wellpath, the combination would become far more consequential.

That exact cross-default/cross-termination question is therefore central.

Bankruptcy makes the control-instrument question more urgent#

the prior analysis indicates that the CFMG MSA most likely continued through Wellpath’s Chapter 11 under the Plan’s blanket assumption mechanism.

The 2019 assignment also placed stock-transfer restrictions in the Wellpath LLC relationship.

The confirmed Plan contains broad language treating assumed contracts as including related agreements and interests unless separately rejected.

This creates a plausible path by which stock-control rights could have continued after May 9, 2025.

But the precise bankruptcy treatment of the CFMG stock agreement remains unknown.

Questions:

• Was the stock agreement separately scheduled?

• Was it considered an executory contract?

• Was it considered an organizational document?

• Was it amended at emergence?

• Did lender ownership alter any rights?

• Did the physician shareholder sign a reaffirmation?

These questions should be treated as Plan implementation issues, not merely historical corporate questions.

The “no ownership overlap” public statement remains important#

In November 2024, Wellpath board co-chair Kip Hallman publicly said CFMG and Wellpath had no ownership overlap and characterized CFMG as primarily physician-owned.

That statement is significant evidence against direct Wellpath stock ownership.

It should remain in the final record.

But the Art Center framework explains why lack of direct ownership is not the end of the analysis.

A company can possess important control rights by contract without owning stock.

Thus:

“Wellpath does not own CFMG stock” and “Wellpath does not control CFMG ownership” are separate propositions.

The first has substantial supporting evidence.

The second remains unresolved until the stock-transfer document is obtained.

Why third-party descriptions of Wellpath owning CFMG carry limited weight#

Some county, media, labor, plaintiff, and advocacy materials describe CFMG as:

• owned by Wellpath;

• acquired by Wellpath;

• absorbed into Wellpath;

• formerly CFMG.

These statements are useful evidence of public operational identity and confusion.

They are weak evidence of actual stock ownership when contradicted by:

• CFMG professional-corporation status;

• bankruptcy treatment;

• Wellpath physician-ownership representations;

• Hallman’s no-overlap statement.

The Lake County Grand Jury’s statement that CFMG is owned by Wellpath is a useful example.

It is an official local-government report and therefore meaningful evidence of what County oversight personnel understood.

But it is not a stock ledger.

The public record should label such descriptions:

governmental-client characterization, not independently verified corporate ownership.

Permanent wording / correction rules#

• Never conflate California Forensic Medical Group, Incorporated with Wellpath CFMG, Inc. f/k/a CFMG Holdings Corp.

• Never call Bazzel, Medrano, Kennedy, Taranath, Herr, Fithian, or another physician a CFMG shareholder without stock evidence.

• Do not state that H.I.G. directly purchased CFMG professional-corporation stock absent acquisition/stock records.

• Do not treat Wellpath bankruptcy language referring to “ownership interests” as an admission that Wellpath owned CFMG stock.

• Do not say the 2025 Plan assigned the CFMG MSA “to the lenders.” Current best reconstruction is continued Wellpath LLC counterparty + Plan assumption/revesting + new upstream ownership.

• Treat Art Center and Carbon Health as California legal/enforcement comparators, not adjudications against CFMG.

• Treat county phrases such as “CFMG/Wellpath,” “now Wellpath,” and “dba Wellpath” as evidence of client/public understanding, not dispositive corporate genealogy.

• Treat \*Smith\*’s same-entity stipulation as binding in that case, not universal merger/alter-ego proof.

• Treat Reynolds , Johnson , Pugh , J.S. , Yang , and similar post-bankruptcy corrections as strong entity-separateness evidence.

• Treat Rule 30(b)(6) use of a Wellpath employee as institutional-knowledge evidence, not automatic alter ego.

• Always distinguish participation , recommendation , approval , veto , implementation , and blocking power .

Tier-one open evidence#

The highest-value missing items remain:

• CFMG-specific stock-transfer restriction / succession agreement.

• CFMG stock ledger and shareholder roster by year.

• CFMG bylaws and Company-Designee appointments.

• Proxy, option, stock-power, escrow, nominee, or power-of-attorney instruments.

• Docket 194 CFMG assumption/cure row and proposed cure amount.

• CFMG board/shareholder minutes from the bankruptcy and emergence period.

• Deficit Funding Loan Agreement.

• UCC/security-interest records.

• Cash/bank signature and treasury authorities.

• Monthly CFMG management-bonus resolutions.

• Smith ECF 156 and full financial-discovery record.

• Full Overfield Chapman termination file/approval chain.

• Utilization-management denial/appeal/override records.

• Current Local Government–California delegation matrix.

• Post-emergence MSA/stock-instrument amendments or reaffirmations.

VI. Why the Issue Matters#

The stakes are practical rather than semantic. Counties need to know which entity is accountable for contracted performance; clinicians need to know where professional authority resides; courts and regulators need entity-specific evidence rather than brand shorthand; and the public needs a record that distinguishes corporate continuity from operational integration. Those distinctions become most important when the actors disagree, when a contract changes hands, when a professional decision conflicts with an economic preference, or when litigation requires a precise answer to who had authority to act.

POST-BANKRUPTCY CALIFORNIA: LOCAL GOVERNMENT–CALIFORNIA#

In March 2026, Wellpath publicly announced a new Local Government–California operating division led by Jessica Mazlum. Wellpath simultaneously described CFMG as a physician-owned professional corporation affiliated with Wellpath's management-services organization.

This is the clearest current public articulation of the model:

CFMG = physician professional corporation

Wellpath = management-services / operating platform

The new division raises important continuity questions:

• Did the underlying CFMG MSA change after bankruptcy?

• Did ownership or control rights change?

• Did new lenders inherit contractual rights over the MSO that affect CFMG?

• Did CFMG physician ownership change?

• What authority does the Local Government–California president have over California clinical operations?

• What authority remains exclusively with CFMG physicians?

• Who reports to Jessica Mazlum?

• Who reports to CFMG's physician officers?

• Who approves physician employment, workload, compensation, and discipline?

These questions should be tested through 2026 county procurement records and current corporate filings.

Why county contracts are different from litigation positions#

A litigation filing is written to win a dispute.

A county contract is written to buy healthcare.

That distinction makes county records unusually valuable.

County procurement files can reveal:

• the bidder;

• the legal contracting party;

• the entity signing the agreement;

• the person signing;

• the entity receiving notices;

• the entity required to maintain insurance;

• the entity indemnifying the County;

• the proposed organizational chart;

• local and regional management;

• staffing requirements;

• medical-director responsibilities;

• clinical-quality requirements;

• EHR obligations;

• physician credentialing;

• pharmacy;

• utilization review;

• claims handling;

• payroll;

• employee relations;

• subcontractors;

• and whether Wellpath is identified as brand, manager, MSO, affiliate, successor, or contractor.

The client-side record is especially important because California counties were not passive observers. They negotiated and monitored the correctional-health programs.

If a county expressly understood that CFMG was the professional contractor and Wellpath the MSO, that is powerful evidence of the intended structure.

If another county called CFMG “now Wellpath,” “dba Wellpath,” or “dba Wellpath Management, Inc.,” that is powerful evidence of public operational identity , but not necessarily accurate corporate law.

The correct analysis is therefore:

What did the contract actually say, and what did the County staff report say?

Those can differ.

VII. Falsification Tests and Evidentiary Limits Note#

The record does not support be read as establishing an unproven motive, an undisclosed shareholder, an unlawful medical override, or a legal conclusion that a court or regulator has not made. The strongest version of the thesis is the one that survives the missing-document test: identify the instrument, minutes, ledger, delegation, approval record, or disagreement event that would materially change the conclusion, then state what has and has not been found. If later primary evidence contradicts a proposition stated here, the correction should be made at the proposition level rather than defended through branding or organizational shorthand.

VIII. Related Articles#

• Article 026 — Dheeraj Taranath and the Enterprise Clinical Layer

• Article 028 — The Missing Stock-Transfer Agreement

• Article 025 — Scott Kennedy and the Financial Side of Physician Governance

The proposition to be tested#

The central proposition in this article is not that every appearance of the Wellpath name proves control, nor that formal CFMG separateness ends the inquiry. The proposition to be tested is narrower: Why do president, director, secretary, and medical-director titles fail to prove stock ownership? A serious legal brief should state that proposition before discussing motive, liability, or remedy because the same document can be highly probative on one dimension and nearly irrelevant on another.

For this subject, the principal evidentiary dimensions are office versus ownership, corporate titles, shareholder proof, and governance correction. The source spine identified in the current public record is: California corporate filings; County contracts; stock-transfer gap; bankruptcy PC model; corrections ledger. Those sources should not be pooled as though they were interchangeable. A county contract speaks most reliably to the county's counterparty and purchased obligations. A management agreement speaks to contractual allocation between the professional corporation and manager. A court order speaks to the matter actually adjudicated. A party filing or corporate announcement remains a representation unless independently adopted or found by a tribunal.

Governance evidence must distinguish office, employment, management title, board membership, shareholder status, delegated authority, and signature authority. These categories can overlap in one person without becoming legally interchangeable. The relevant capacity must be identified for each act. The practical advantage of that method is that it prevents a common failure in complex-enterprise investigations: using a true fact about one relationship as proof of a different relationship. A shared brand may show integration; a W-2 may show payroll identity; a contract signature may show authority to bind a corporation; an officer title may show corporate office. None automatically proves stock ownership or final clinical authority.

The charging or enforcement threshold, if any regulator ever considered one, would therefore require an evidence chain rather than a collage: identify the protected or regulated function; identify the actor with formal authority; reconstruct the first operative decision; identify the person or entity that could approve, reject, modify, or reverse it; and verify who implemented the result. Until that chain is complete, the proper classification is evidence, inference, or unresolved question—not adjudicated fact.

Weighing the evidence#

The evidentiary hierarchy for Officer Is Not Owner: The Most Important Corporate-Governance Correction in the Record should begin with contemporaneous primary instruments and end with retrospective shorthand. Executed contracts, amendments, assignments, board resolutions, authenticated corporate records, court orders, government payroll or labor records, and formal agency records ordinarily deserve more weight on the proposition they were created to establish than marketing language or later summaries. Even among primary materials, however, purpose matters. A contract can establish contractual rights without proving that those rights were exercised; a tax record can establish reporting without deciding every common-law employer factor; a bankruptcy schedule can establish debtor treatment without answering professional-governance questions for a nondebtor corporation.

The article's existing record illustrates why that hierarchy matters.ithin its evidentiary lane. How could a California physician-owned professional corporation be identified in federal corporate-disclosure filings as the “corporate parent” of Wellpath LLC, a national management entity, while public corporate materials describe CFMG as a Wellpath affiliate?

A prosecutor, defense lawyer, regulator, or investigative editor should ask five questions of every source: Who created it? What legal or business purpose did it serve? What date and entity does it concern? Is the statement a recital, operative term, allegation, stipulation, finding, or marketing representation? What independent record could confirm or contradict it? Applying those questions consistently is more valuable than multiplying citations that all derive from the same underlying assertion.

This also defines how contradictions should be handled. When two records use different labels, the first step is not to accuse one of being false. The first step is to determine whether the records were answering different questions. Only after normalizing entity, date, capacity, forum, and purpose should a remaining contradiction be treated as substantive. That discipline makes the article stronger for both sides because it identifies where the record genuinely conflicts and where the conflict is merely semantic.

Chronology as a control test#

Chronology is often more probative than organizational charts. The decisive question is not merely who possessed authority on paper, but when a decision became operative and what happened immediately before and after that moment. A later board vote, HR notice, county communication, or litigation position may confirm, ratify, or explain an earlier act without proving who made the initial decision. Conversely, an early recommendation may have no legal effect until the authorized professional or contracting entity adopts it.

For Officer Is Not Owner: The Most Important Corporate-Governance Correction in the Record, the chronology should be reconstructed with document-level precision. Investigators should place each significant contract, amendment, email that has entered the public record, board action, personnel or agency event that is lawfully publishable, and court filing on a single timeline. Each entry should identify the actor, capacity, entity, action verb, and legal effect. Terms such as “recommended,” “approved,” “directed,” “implemented,” “ratified,” “reported,” and “terminated” are not synonyms. The wording can reveal whether a participant supplied information, exercised discretion, or merely carried out another actor's decision.

The current article supplies anchor points that should remain central. What happened to the CFMG shareholder, board, and Company Designee structure during the 2018–2019 Wellpath transition while Herr was president? Public Wellpath proposal materials identify Medrano as a Regional Medical Director and state that he joined Wellpath in 2017.

A robust chronology is also the best protection against overstatement. If the alleged controlling act occurred before the supposedly controlling actor entered the process, that theory weakens. If a professional body acted only after implementation, a claim that it supplied the first operative decision requires qualification. If the public record shows independent deliberation before implementation, that evidence materially strengthens the formal-independence account. The analysis therefore must treat time as an evidentiary variable, not just background narrative.

How each source is used#

The following public authorities are tied to defined propositions in this article. They are not interchangeable: each is cited for the institutional purpose it can actually prove, and none is treated as a universal finding about ownership, employment, liability, or professional control.

• California Corporations Code § 13401.5, Moscone-Knox Professional Corporation Act. Used here as the professional-corporation ownership and licensed-person framework relevant to shareholder, director, officer, and professional-employee questions.
• California Business and Professions Code § 2400. Used here as the statutory anchor for California's prohibition on the unlicensed corporate practice of medicine.
• 2012 CFMG Management Services Agreement — California Forensic Medical Group, Incorporated and California Forensic Management Group, Inc., Dec. 31, 2012. Used here as operative baseline for the allocation of management functions, physician-reserved responsibilities, and the manager/professional-corporation relationship.
• 2019 Assignment of Management Services Agreement, effective Jan. 1, 2019 — CFMG remained the Company while Wellpath LLC became the Manager. Used here as dated evidence of management succession without, by itself, eliminating CFMG's separate professional-corporation identity.
• H.I.G. Capital, 'H.I.G. Capital Announces Strategic Investment in California Forensic Medical Group,' Jan. 7, 2013. Used here as first-party transaction evidence for the 2013 investment and founder-era enterprise history, but not a shareholder ledger for the California professional corporation.
• Federal Rule of Civil Procedure 7.1, Disclosure Statement. Used here as the federal corporate-disclosure framework relevant to testing parent, subsidiary, and interested-entity terminology without converting disclosure language into a universal ownership finding.
• Johnson v. County of Alameda, N.D. Cal. No. 3:23-cv-04069, ECF No. 76 (Mar. 2026). Used here as a public litigation correction distinguishing CFMG from Wellpath Management, Inc. and the debtor-side entities.

Sources and authorities#

1. California Corporations Code § 13401.5, Moscone-Knox Professional Corporation Act — https://leginfo.legislature.ca.gov/faces/codes\_displaySection.xhtml?lawCode=CORP&sectionNum=13401.5.
2. California Business and Professions Code § 2400 — https://leginfo.legislature.ca.gov/faces/codes\_displaySection.xhtml?lawCode=BPC&sectionNum=2400.
3. 2012 CFMG Management Services Agreement — California Forensic Medical Group, Incorporated and California Forensic Management Group, Inc., Dec. 31, 2012 — https://www.prisonlegalnews.org/news/publications/california-forensic-medical-group-incorporated-management-services-agreement/
4. 2019 Assignment of Management Services Agreement, effective Jan. 1, 2019 — CFMG remained the Company while Wellpath LLC became the Manager — https://www.prisonlegalnews.org/media/publications/California\_Forensic\_Medical\_Group\_Assignment\_of\_Management\_Services\_Agreement.pdf
5. H.I.G. Capital, 'H.I.G. Capital Announces Strategic Investment in California Forensic Medical Group,' Jan. 7, 2013 — https://hig.com/news/h-i-g-capital-announces-strategic-investment-in-california-forensic-medical-group/
6. Federal Rule of Civil Procedure 7.1, Disclosure Statement
7. Johnson v. County of Alameda, N.D. Cal. No. 3:23-cv-04069, ECF No. 76 (Mar. 2026) — https://docs.justia.com/cases/federal/district-courts/california/candce/3%3A2023cv04069/416712/76

Citation rule: These sources support only the propositions identified in the article and source analysis. A party filing remains a party position unless adopted by a court; a corporate announcement remains a corporate representation; a contract proves allocated rights but not necessarily implementation; and a regulator's guidance or enforcement position is not an adjudication against CFMG unless a cited matter says so.